Novo Nordisk's Buyback Bet: Can Management's Conviction Outweigh the Street's Doubts?

Novo Nordisk buys back shares at 280.34 DKK while Deutsche Bank cuts target to 265 DKK, citing pipeline setbacks and competition.

The arithmetic of Novo Nordisk's current predicament is hard to reconcile. Management has been buying its own stock at an average price of 280.34 Danish kroner per share, committing roughly 8.4 billion kroner of a 15-billion-kroner repurchase program since February. The shares last traded in Copenhagen at 298.10 kroner after a modest Friday rebound. Yet the very same week, Deutsche Bank flipped its rating to Sell and slashed its price target by 9 percent to 265 kroner — a level that implies the buyback is being executed at prices the bank considers roughly 12 percent too rich.

That tension between internal conviction and external skepticism sits at the heart of the investment case. The buyback, which has accumulated nearly 29.9 million B-shares and now represents about 1 percent of the company's capital, signals that management views the equity as undervalued. Deutsche Bank's Emmanuel Papadakis, by contrast, sees "mixed" second-quarter numbers, persistent growth concerns, and a failed Phase 3 trial for Ziltivekimab in cardiovascular disease as reasons to step aside.

The market has yet to pick a side. The stock slipped between 2.4 percent and 3 percent in Copenhagen following the downgrade, closing at 295.45 kroner before Friday's 0.97 percent bounce. In German trading, the shares hover around 39.35 to 39.39 euros, down roughly 13 percent over the past month and 11 percent year-to-date. The 52-week high sits 28 percent above current levels, while the distance to the 52-week low of 30.25 euros is a comfortable 30 percent cushion.

A Pipeline Setback That Refuses to Fade

The Ziltivekimab failure is not merely a clinical disappointment — it carries a hard financial cost. The second quarter absorbed 6.3 billion kroner in non-recurring impairments, including 4.0 billion kroner tied to the Monlunabant pipeline project. Those write-downs underscore a broader vulnerability: beyond the GLP-1 core, the pipeline is not delivering. Deutsche Bank's downgrade was predicated on lower medium-term revenue estimates stemming directly from the cardiovascular study's failure.

The competitive pressure compounds the problem. Eli Lilly's oral weight-loss drug secured its first European approval in August, directly challenging Novo Nordisk's Wegovy franchise. Meanwhile, a Dutch court's August injunction against Ceban Ziekenhuisfarmacie over a compounded semaglutide nasal spray — while a legal victory for Novo Nordisk — illustrates the constant energy required to defend the patent estate against imitators. With annualized volatility at 40 percent, the market is clearly pricing in a wide range of outcomes.

The Bull Case Hinges on China and Momentum

Against the bearish narrative stands a genuinely promising regulatory development. China's NMPA has accepted the marketing application for oral Wegovy, opening a potential pathway into the world's second-largest pharmaceutical market. J.P. Morgan analysts see GLP-1 weight-loss revenue in China reaching up to 30 billion yuan within five to seven years, up from an estimated 3 to 4 billion yuan today.

The oral formulation's US traction adds credibility. Management reports more than five million cumulative prescriptions within 30 weeks of launch, capturing 90 percent of the oral US weight-loss market. JPMorgan's August 25 price target increase to 275 kroner from 250 kroner suggests at least one major house sees the risk-reward shifting favorably.

The technical picture offers some support as well. The stock trades near its 100-day moving average of approximately 39.40 euros, a level that could serve as a floor if the buyback continues and the China narrative gains traction. The fact that management is repurchasing shares at prices significantly above current levels reinforces the message that they believe the market has it wrong.

What Could Break the Impasse

The immediate catalyst is an investor update next month, which JPMorgan expects to provide a comprehensive pipeline overview, including next-generation obesity and diabetes candidates. That presentation could either validate Deutsche Bank's caution or demonstrate that the growth engine has more to give.

A decision from China's NMPA on the Wegovy application — for which no timeline has been announced — would be the next major regulatory milestone. Approval would open a substantial distribution channel and strengthen the bull case considerably.

The bearish scenario is equally clear: if the stock loses the 100-day average and additional downgrades follow Deutsche Bank's pattern, the Sell rating could quickly transform from a single opinion into a trend. The buyback, in that scenario, becomes an expensive gesture lacking fundamental support.

For now, the stock sits at a crossroads where management's checkbook and the analyst community's spreadsheets tell different stories. The coming weeks — with the investor update and potential NMPA news — will determine which version of Novo Nordisk's future is closer to reality.